A peptide drug has to exist as an actual, physical molecule before anyone can study whether it works, and how that molecule gets made is its own distinct area of pharmaceutical science, separate from the clinical trials that test it. Broadly, peptide manufacturing splits into two main approaches, chemical synthesis and recombinant biological production, and the choice between them shapes everything from manufacturing cost to how consistent each batch turns out.
Solid-Phase Peptide Synthesis
Solid-phase peptide synthesis (SPPS), developed in the 1960s, builds a peptide chain one amino acid at a time, anchored to a solid resin bead. Each amino acid is added in sequence, with protective chemical groups attached and removed at each step to control exactly where the next link in the chain forms, and the finished chain is then cleaved off the resin and purified. This approach is well-suited to shorter peptides, generally under 50 or so amino acids, and gives manufacturers precise, repeatable control over the exact sequence being built. Its main drawback is scale: each coupling step has some yield loss, so efficiency drops as the chain gets longer, which is part of why SPPS alone becomes less practical for larger peptides and most small proteins.
Recombinant DNA Production
Recombinant production takes a fundamentally different route: instead of assembling the peptide chemically, scientists insert the genetic sequence coding for it into a host organism, commonly a bacterium like E. coli or a yeast strain, and let that organism's own cellular machinery manufacture the peptide as it grows in a fermentation tank. The peptide is then extracted and purified away from the host cell's other proteins. This approach scales well for larger or more complex sequences and is the backbone of how many therapeutic proteins and some longer peptide hormones have been manufactured for decades, insulin being the most well-known example, discussed in this site's history of peptide therapeutics.
Why Many GLP-1 Drugs Use a Hybrid Approach
Modern GLP-1 drugs illustrate why the two approaches aren't always an either-or choice. Semaglutide and related GLP-1 analogs are built around a peptide backbone that can be produced using fermentation-based or chemical synthesis methods, which is then chemically modified afterward, most notably through the attachment of a fatty-acid side chain, to extend the drug's half-life in the body, a modification process this site covers separately in its guide to half-life extension. That final chemical conjugation step is typically done through synthetic chemistry regardless of how the base peptide chain itself was produced, which is why a single modern GLP-1 drug's manufacturing process can genuinely combine both major production philosophies rather than relying on just one.
Why This Matters for Quality and Safety
Manufacturing method matters directly for drug safety and consistency, which is also why it's a central part of FDA review. Impurity profiles differ: chemical synthesis can leave trace amounts of coupling reagents or incompletely formed sequences, while recombinant production can carry host-cell protein or DNA residues that must be purified out. Batch-to-batch consistency is also a core part of what an FDA-approved manufacturing process has to demonstrate before and after approval, which is part of why Eli Lilly's 2026 decision to delay retatrutide's FDA application specifically cited unresolved manufacturing data, discussed elsewhere on this site, rather than a clinical efficacy or safety problem.
What This Means for the Research-Chemical Market
This is also where a meaningful, verifiable safety gap opens up between FDA-approved peptide drugs and unregulated research-chemical peptides sold online. An approved manufacturer's process, whichever method it uses, is subject to FDA facility inspection, validated quality-control testing, and documented purity standards. A peptide sold as "research use only" from an unregulated supplier typically carries none of those enforced guarantees, which is the core reason this site's safety coverage repeatedly flags sourcing and purity as a distinct risk from the compound itself.